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Abstract
This study compared gait speed changes after CSF tap test in patients with idiopathic normal pressure hydrocephalus pre-
senting with various gait phenotypes (frontal, parkinsonian, normal, or other). All patients improved, except those with 
parkinsonian gait.
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Introduction
Gait disorders are the hallmark feature of patients with idi-
opathic normal pressure hydrocephalus (iNPH) (Relkin et al. 
2005). INPH patients present various gait phenotypes from 
normal gait to severe frontal or parkinsonian gait (Morel 
et al. 2019). The variability of these phenotypes may be 
due to the severity of iNPH or influenced by comorbid 
neurological (i.e., vascular lesions) and non-neurological 
(i.e., arthritis) diseases (Stolze et al. 2001). To assess the 
reversibility of gait impairment in iNPH, the CSF tap test 
represents a widely used prognostic procedure (Krauss and 
Halve 2004). However, the influence of gait phenotypes on 
gait changes after CSF tap test has never been studied in 
patients with iNPH. Therefore, we aimed to compare gait 
speed changes after CSF tap test among the various gait 
phenotypes presented by patients with iNPH. Establishing 
which gait phenotype in iNPH is associated with good clini-
cal outcomes after CSF tap test may improve the identifica-
tion of appropriate candidates for shunt surgery.
Methods
A total of 77 consecutive iNPH patients from the Geneva 
iNPH cohort (Allali et al. 2017) were included in this retro-
spective study (age 76.1 ± 6.2 years; 32.5% female). Study 
procedures have been previously described (Allali et al. 
2017). Briefly, patients were referred for suspicion of iNPH 
based on gait disturbances, cognitive impairment, and/or 
urine incontinence. Inclusion criteria were patients with a 
diagnosis of possible or probable iNPH (i), able to walk 
without assistance (ii), a video recording of their gait pre-
CSF tap test (iii), and a measure of gait speed pre- and post-
CSF tap test (iv). Exclusion criteria were any acute medical 
condition in the 3 months before the examination and a diag-
nosis of secondary NPH. INPH was diagnosed according 
to the international criteria (Relkin et al. 2005) after a case 
conference involving neurologists, neuropsychologists, and 
physical therapists (possible iNPH in 87%; probable iNPH 
in 13%). Gait phenotypes were evaluated by two assessors 
(EM and GA)—blind for the gait changes after CSF tap 
test—with a substantial agreement (kappa, 0.73), who clas-
sified the phenotypes as normal, frontal, parkinsonian, and 
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other. As previously described (Verghese et al. 2002), frontal 
gait was defined by short steps, a wide base of support, and 
a magnetic component (reduced step height); parkinsonian 
gait was defined by short and/or shuffling steps, flexed pos-
ture, reduced arm swing, and normal base; normal gait was 
defined by the absence of any clinical gait abnormalities, and 
other gait was defined by any other clinical gait abnormali-
ties (Morel et al. 2019). Patients walked at their comfort-
able speed on a 10-m walkway before the CSF tap test and 
24 h after, as previously suggested (Virhammar et al. 2012). 
Walking speed was calculated from the trajectory of reflec-
tive markers attached to the patient’s heels, evaluated by an 
optoelectronic system (Vicon Mx3+, Oxford Metrics, UK). 
Statistical analysis used ANOVA or Kruskal–Wallis test, as 
appropriate, to evaluate differences between gait phenotypes. 
Gait speed changes were calculated according to the follow-
ing formula: (gait  speedpost-CSF tap test − gait  speedpre-CSF tap test)/
[(gait  speedpost-CSF tap test + gait  speedpre-CSF tap test)/2]. Univari-
able linear regressions evaluated the relationship between 
gait speed changes (dependent value) and each gait pheno-
type (independent value). Multivariable linear regressions 
were adjusted for age, gender, comorbidities, white matter 
changes assessed by the age-related white matter change 
scale (Wahlund et al. 2001), and mini-mental state exami-
nation (MMSE). The Ethical Review Board of the Geneva 
University Hospitals approved the study (Protocol 09-160R).
Results
Clinical characteristics are presented in Table 1: 30% of the 
patients presented with a normal gait, 25% with a frontal 
gait, 15% with a parkinsonian gait, and 30% with other gait 
abnormalities. Global cognition and white matter changes 
Table 1  Characteristics of the participants (n = 77)
Results are given in mean ± standard deviation, unless indicated otherwise
*Significance level was set at p < 0.05
a Patients presented significant differences in comparison with the other groups
b Diabetes, chronic heart failure, hypertension, depression, stroke, Parkinson disease, chronic obstructive pulmonary disease, angina, and myocar-
dial infarction
c Diabetes, hypertension, hypercholesterolemia, body mass index > 30, and smoking
d Myocardial infarction, angina, arrhythmia, and chronic heart failure
e Transient ischemic attack and stroke
f Age-related white matter changes quantify the burden of white matter disease in the whole brain and its subregions
g Delta of gait speed was calculated as follows: [(gait speed post-tap test) − (gait speed pre-tap test)]/[(gait speed pre-tap test) + (gait speed post-
tap test)]/2)
Normal gait (n = 23) Frontal gait (n = 19) Parkinsonian gait (n = 12) Other gait (n = 23) p value
Age, years 75.13 ± 7.88 76.89 ± 4.69 75.08 ± 5.74 76.00 ± 5.76 0.717
Gender, n (% female) 7 (30.4) 5 (26.3) 3 (25.0) 10 (43.5) 0.590
Disease duration, months 29.09 ± 23.77 43.79 ± 38.67 40.50 ± 20.33 42.75 ± 31.54 0.319
Comorbidity (0–10)b 1.26 ± 1.01a 2.00 ± 1.16 2.00 ± 1.04 2.25 ± 0.79 0.008*
Medication, n 2.87 ± 2.30a 4.42 ± 1.17 4.83 ± 2.73 4.15 ± 2.46 0.047*
Mini-mental state (0–30) 26.30 ± 4.99 25.68 ± 4.88 24.67 ± 5.33 26.78 ± 3.63 0.704
Risk factors
 Vascular (0–5)c 1.13± 0.87 1.26 ± 0.73 1.50 ± 0.80 1.50 ± 1.15 0.675
 Cardiovascular (0–4)d 0.04 ± 0.21a 0.37 ± 0.50 0.08 ± 0.29a 0.25 ± 0.44 0.028*
 Cerebrovascular (0–2)e 0.04 ± 0.21 0.16 ± 0.38 0.17 ± 0.39 0.00 ± 0.00 0.154
White matter  changesf
 Frontal (0–6) 2.65 ± 1.80 2.21 ± 1.51 2.08 ± 1.38 2.45 ± 1.40 0.741
 Parieto-occipital (0–6) 2.26 ± 2.12 1.89 ± 1.85 1.83 ± 1.64 2.40 ± 1.67 0.677
 Temporal (0–6) 0.61 ± 1.27 0.42 ± 1.07 0.75 ± 1.42 0.80 ± 1.32 0.702
 Basal ganglia (0–6) 0.52 ± 0.85 0.58 ± 0.96 0.58 ± 0.79 0.45 ± 0.83 0.969
 Infratentorial (0–6) 0.26 ± 0.62 0.26 ± 0.65 0.00 ± 0.00 0.30 ± 0.66 0.480
 Total score (0–30) 6.30 ± 5.45 5.37 ± 4.21 5.25 ± 3.84 6.40 ± 4.80 0.814
Gait speed
 Pre-CSF tap test (m/s) 0.90 ± 0.19a 0.51 ± 0.21 0.55 ± 0.18 0.76 ± 0.21 < 0.001*
 Delta (m/s)g 0.12 ± 0.14 0.31 ± 0.31 0.17 ± 0.47 0.10 ± 0.14 0.053
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were similar across the various gait phenotypes. The average 
gait speed of the cohort was relatively slow (0.71 ± 0.25 m/s); 
patients with frontal and parkinsonian gait were the slow-
est walkers (0.51 ± 0.18 m/s and 0.55 ± 0.18 m/s, respec-
tively). Except for those with parkinsonian gait, all patients 
significantly improved their gait speed after CSF tap test 
(Fig. 1). Patients with frontal gait improved their gait speed 
to a greater extent in comparison to other gait phenotypes 
(delta: 0.31 ± 0.31; p value < 0.001). Frontal gait was sig-
nificantly associated with gait speed improvement after CSF 
tap test, even after adjusting on age, gender, comorbidities, 
white matter changes, and MMSE (β: 0.311 [95% CI 0.058; 
0.334]; p value: 0.006). Normal gait, parkinsonian gait, and 
other gait abnormalities were not significantly associated 
with gait speed improvement, after adjusting on age, gender, 
comorbidities, white matter changes, and MMSE (normal 
gait: β: − 0.197 [95% CI − 0.262; 0.028]; p value: 0.112; Par-
kinsonian gait: β: 0.031 [95% CI − 0.150; 0.197]; p value: 
0.788; other gait abnormalities: β: − 0.160 [95% CI − 0.241; 
0.046]; p value: 0.179).
Discussion
This study showed that gait improvement after CSF tap 
test varies across gait phenotypes: frontal gait is associated 
with the greatest gait improvement after CSF tap test, while 
patients with parkinsonian gait did not show any significant 
gait speed changes.
In comparison with other gait phenotypes, iNPH patients 
with frontal gait dramatically improved their gait speed after 
CSF tap test (delta: 0.31 ± 0.31; p value < 0.001). Patients 
with frontal gait presented the lowest gait speed at baseline 
and, therefore, had the greatest potential of improvement, as 
previously described (Kahlon et al. 2007). The present find-
ings partially contrast with a previous study, showing that 
hypokinesia responds more to CSF tap test than frontal signs 
including disequilibrium (Bugalho and Guimarães 2007); 
in comparison with this previous study, we focused here on 
gait phenotypes and not on individuals neurological signs. 
Furthermore, the patients included in Bugalho’s study were 
more severely affected (mean gait speed: 0.33 ± 0.20 m/s) in 
comparison to our study (0.71 ± 0.25 m/s). The role of irre-
versible comorbid neurological conditions may also explain 
these differences in terms of gait reversibility after CSF tap 
test: the presence of parkinsonism in patients with higher 
level gait disorders (such as iNPH) has been associated 
with Alzheimer’s pathology (Allali et al. 2018). Another 
explanation for this discrepancy in CSF response between 
iNPH patients with frontal and parkinsonian gaits may refer 
to the brain structures and the pathogenesis associated with 
both these gait phenotypes: older adults with parkinsonian 
gait present more severe executive deficits in comparison 
to those with frontal gait, suggesting the involvement of 
different brain regions between both these gait phenotypes 
(Ambrose et al. 2006).
Patients with a clinical phenotype of normal gait also 
demonstrated a gait improvement after CSF tap test. The 
relatively high proportion of patients with normal gait (30%) 
may be explained by the following reasons. First, patients 
were included at an early stage of the disease course, where 
clinical gait abnormalities may not be evident. Second, 
patients have been referred, because the suspicion of iNPH 
was solely based on cognitive impairment and/or urinary 
incontinence. Third, patients may complain of gait impair-
ments in challenging situations (e.g., uneven ground) or 
balance impairments that were not clinically evident in the 
secure setting of a gait laboratory. Fourth, they presented 
Fig. 1  Gait speed changes. Gait 
speed changes are presented 
before and 24 h after CSF tap 
test. aSignificance level was set 
at p < 0.05
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fewer comorbidities that may affect gait. These results sug-
gest that CSF tap test could also be considered at the earliest 
stages of iNPH when patients complain about their gait, but 
no clinical gait abnormality is diagnosed by physicians.
The variability of the gait phenotypes in our cohort of 
iNPH patients may be explained by comorbidities (Stolze 
et al. 2001). Neurological (i.e., Alzheimer’s disease or cer-
ebrovascular disease) and non-neurological (i.e., osteoarthri-
tis) comorbidities likely contribute to each pathological gait 
phenotype, as highlighted by the highest score of comorbidi-
ties in the pathological gait phenotypes.
The main strength of this study is confirming the inter-
est and the validity of a non-expensive clinical approach 
(without any gait analysis system but only the clinician’s 
eyes). However, the validity of the clinical examination 
(i.e., clinical gait characteristics) is not perfect and prone 
to an interrater variability. Having a better quantification 
of neurological and non-neurological comorbidities would 
allow a better sense of the influence of comorbidity on each 
gait phenotype. A post-mortem pathological examination is 
missing and would be of interest, especially in this cohort 
including mainly patients with possible iNPH (87%), who 
may present either a comorbid neurological condition along 
with iNPH or present an iNPH mimic. Finally, future stud-
ies should confirm these results by evaluating the predictive 
value of clinical gait phenotypes after shunting.
Conclusion
Among gait phenotypes, frontal gait in patients with iNPH 
is associated with the largest gait improvement after CSF 
tap test. This study suggests that a clinical classification of 
gait phenotypes in patients with iNPH may inform about 
the reversibility of gait disabilities. Future studies should 
include long-term clinical outcomes after shunt procedure to 
confirm that frontal gait in iNPH patients may present a good 
clinical outcome in comparison to other gait phenotypes.
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